Absci Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
15.9%projected annual EPS growth
Analyst Coverage
9analysts covering
FY Revenue (est.)
$2.2Mnext fiscal year
FY EPS (est.)
-$0.81next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
ABS-201 HEADLINE Phase 1/2a Trial Progress QuarterlyTarget: Interim 13-week hair regrowth data in H2 2026 and full 26-week proof-of-concept data in early 2027
Cash Runway Quarterly125.7MTarget: Sufficient to fund operations into the first half of 2028
Partner Program Revenue Quarterly215KTarget: Signing one or more partnerships, including with a Large Pharma company, in 2026
Watch Items
- ABS-201 Phase 2 Endometriosis Trial InitiationTrigger: Planned initiation in Q4 2026Action: Monitor regulatory submissions, clinical advisory board updates, and trial site activation.
- ABS-201 Preliminary Safety, Tolerability, and PK DataTrigger: Expected release in Q2 2026Action: Evaluate pharmacokinetic modeling and safety profiles to confirm the targeted dosing interval of 2-3 injections over 6 months.
Research as of 19 Jun 2026